Edition:
India

Alliqua BioMedical Inc (ALQA.OQ)

ALQA.OQ on NASDAQ Stock Exchange Capital Market

2.04USD
8:47pm IST
Change (% chg)

$0.01 (+0.49%)
Prev Close
$2.03
Open
$2.07
Day's High
$2.10
Day's Low
$2.04
Volume
9,510
Avg. Vol
16,132
52-wk High
$8.47
52-wk Low
$1.76

Latest Key Developments (Source: Significant Developments)

Alliqua Biomedical Says Has Right To Terminate Agreement With Celularity, Provided Co Pays $1.45 Mln Fee
Saturday, 6 Jan 2018 

Jan 5 (Reuters) - Alliqua Biomedical Inc ::ALLIQUA BIOMEDICAL SAYS HAS RIGHT TO TERMINATE ASSET PURCHASE AGREEMENT WITH CELULARITY, PROVIDED CO PAYS TERMINATION FEE OF $1.45 MILLION - SEC FILING.ALLIQUA BIOMEDICAL INC - CELULARITY MAY BE OBLIGATED TO PAY A $3 MILLION REVERSE TERMINATION FEE IF ASSET PURCHASE AGREEMENT IS TERMINATED BY CO.  Full Article

Alliqua Biomedical Announces Definitive Asset Purchase Agreement With Celularity Inc
Saturday, 6 Jan 2018 

Jan 5 (Reuters) - Alliqua Biomedical Inc ::ALLIQUA BIOMEDICAL, INC. ANNOUNCES DEFINITIVE ASSET PURCHASE AGREEMENT WITH CELULARITY, INC..ALLIQUA BIOMEDICAL INC - DEAL FOR $29.0 MILLION.ALLIQUA BIOMEDICAL - AS PER DEAL, CELULARITY WILL ACQUIRE ALL OF PROPERTY, ASSETS AND RIGHTS RELATING TO CO'S ADVANCED BIOLOGIC WOUND CARE BUSINESS.ALLIQUA BIOMEDICAL - AS PER DEAL, CELULARITY WILL ALSO ACQUIRE ALL OF PROPERTY, ASSETS AND RIGHTS RELATING TO CO'S ULTRAMIST THERAPY SYSTEM.ALLIQUA BIOMEDICAL INC - CO'S BOARD OF DIRECTORS UNANIMOUSLY APPROVED ENTERING INTO AGREEMENT.ALLIQUA BIOMEDICAL INC - NO DEBT OR SIGNIFICANT LIABILITIES ARE BEING ASSUMED BY CELULARITY IN TRANSACTION.  Full Article

Alliqua BioMedical engages Cowen to assist in evaluating potential strategic alternatives
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Alliqua BioMedical Inc :Alliqua BioMedical Inc engages Cowen to assist in evaluating potential strategic alternatives.Alliqua BioMedical Inc - engaged Cowen as its independent financial advisor to assist co in evaluating potential strategic alternatives​.  Full Article

Alliqua Biomedical says co and Celgene entered into side letter agreement
Thursday, 16 Mar 2017 

Alliqua Biomedical Inc : On March 13, 2017, co and Celgene entered into a side letter agreement - sec filing . co, chairman Jerome Zeldis entered into side letter agreement; Zeldis to conditionally waive MFN adjustment in securities purchase deal . Celgene agreed to waive MFN adjustment in spa to extent MFN adjustment would cause Celgene to own in excess of 19.9% of co's common stock Further company coverage: [ALQA.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Alliqua Biomedical reports Q3 GAAP loss per share $0.30
Friday, 4 Nov 2016 

Alliqua Biomedical Inc : Reports third quarter and nine-months fiscal year 2016 financial results . Q3 non-GAAP loss per share $0.16 from continuing operations . Q3 GAAP loss per share $0.30 . Q3 revenue $4.9 million versus I/B/E/S view $4.8 million . Sees FY 2016 revenue $18.3 million to $19 million . Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $-0.74, revenue view $18.7 million -- Thomson Reuters I/B/E/S.  Full Article

Alliqua BioMedical sees Q3 revenue about $4.85 million
Thursday, 6 Oct 2016 

Alliqua BioMedical Inc : Alliqua Biomedical Inc. announces preliminary third quarter of fiscal year 2016 revenue; earnings conference call scheduled for November 4th . Sees Q3 revenue about $4.85 million . Q3 revenue view $4.7 million -- Thomson Reuters I/B/E/S .Sees Q3 revenue up about 16 percent.  Full Article

Alliqua Biomedical Inc Q2 adjusted loss per share $0.19
Tuesday, 9 Aug 2016 

Alliqua Biomedical Inc : Alliqua Biomedical, Inc. Reports second quarter and six months fiscal year 2016 financial results . Q2 earnings per share $0.18 . Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Q2 revenue $5.5 million versus I/B/E/S view $5.4 million . Sees FY 2016 revenue $20 million to $22 million . Alliqua biomedical inc sees fy 2016 total revenue from continuing operations of approximately $18.3 million to $20.3 million .FY2016 revenue view $21.3 million -- Thomson Reuters I/B/E/S.  Full Article

Alliqua Biomedical sees 2016 revenue $20 mln to $22 mln
Thursday, 7 Jul 2016 

Alliqua Biomedical Inc : Alliqua Biomedical Inc and BSN Medical Inc announce definitive agreement on distribution rights for Sorbion dressing products in the U.S., Canada and Latin America; Alliqua updates fiscal year 2016 outlook . Sees FY 2016 revenue $20 million to $22 million . Will use about $1.75 million of proceeds of deal to reduce outstanding debt balance in accordance with credit agreement . Updating revenue guidance for fiscal year 2016 to account for expected impact of deal of distribution rights for Sorbion products . BSN to pay co up to $4.4 million for purchase by BSN of rights out of co's existing distribution deal with former Sorbion GMBH & Co KG .FY 2016 revenue view $21.9 million -- Thomson Reuters I/B/E/S.  Full Article

Alliqua Biomedical sees Q2 revenue about $5.4 mln
Thursday, 7 Jul 2016 

Alliqua Biomedical Inc : Alliqua biomedical, inc. Announces preliminary second quarter of fiscal year 2016 revenue; earnings conference call scheduled for august 9th . Sees q2 revenue about $5.4 million . Sees q2 revenue up about 72 percent . Q2 revenue view $5.3 million -- Thomson Reuters I/B/E/S .Says expects q2 total revenue of approximately $5.4 million.  Full Article

Alliqua Biomedical reports Q1 loss per share of $0.28
Tuesday, 10 May 2016 

Alliqua Biomedical Inc : Fy2016 revenue view $22.5 million -- Thomson Reuters I/B/E/S . Alliqua biomedical, inc. Reports first quarter financial results . Q1 non-gaap loss per share $0.20 . Q1 loss per share $0.28 . Q1 revenue $4.6 million versus i/b/e/s view $5 million . Sees fy 2016 revenue up about 46 to 60 percent . Sees fy 2016 revenue $22 million to $24 million .Q1 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Alliqua Biomedical Says Has Right To Terminate Agreement With Celularity, Provided Co Pays $1.45 Mln Fee

* ALLIQUA BIOMEDICAL SAYS HAS RIGHT TO TERMINATE ASSET PURCHASE AGREEMENT WITH CELULARITY, PROVIDED CO PAYS TERMINATION FEE OF $1.45 MILLION - SEC FILING